A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency

NCT02382939 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Adult Growth Hormone Deficiency
Growth Hormone Disorder

Interventions

DRUG: somapacitan
DRUG: somatropin

Sponsor

Novo Nordisk A/S